Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06680128




Registration number
NCT06680128
Ethics application status
Date submitted
28/10/2024
Date registered
8/11/2024
Date last updated
8/11/2024

Titles & IDs
Public title
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
Scientific title
A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis MRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Secondary ID [1] 0 0
GBP560_001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Japanese Encephalitis Virus Disease 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Neurological 0 0 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - GBP560-A
Treatment: Other - GBP560-B
Treatment: Other - IXIARO
Treatment: Other - IMOJEV
Treatment: Other - Normal Saline (Placebo)

Experimental: Test group 1-1 (GBP560-A) - Low dose level(3µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Experimental: Test group 1-2 (GBP560-B) - Low dose level (3µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Experimental: Test group1-3 (GBP560-A) - Mid dose level (15µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Experimental: Test group1-4 (GBP560-B) - Mid dose level (15µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Experimental: Test group1-5 (GBP560-A) - High dose level (50µg) for GBP560-A in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Experimental: Test group1-6 (GBP560-B) - High dose level (50µg) for GBP560-B in stage 1. Participants will receive 2 doses of one of the test vaccines at 4-week intervals, respectively.

Active comparator: Control group1 (IXIARO®) - Participants will receive 2 doses of one of the active comparators (IXIARO®, 6 Antigen Unit, corresponding to a potency of = 460 ng ED) at 4-week intervals, respectively in Stage 1 and Stage 2.

Active comparator: Control group2 (IMOJEV®) - Participants will receive 1 dose of placebo saline and 1 dose of another active comparator (IMOJEV®, 4.0 - 5.8 log PFU) at 4-week intervals, respectively in Stage 1 and Stage 2.

Experimental: Test group 2-1 (GBP560-A or B) - Participants will receive 2 intramuscular injections of the test vaccines in stage 2.

1st will be on Visit 2 and 2nd will be on Visit 5, in line with the selected dose regimen in stage 1.

Experimental: Test group 2-2 (GBP560-A or B) - Participants will receive 2 intramuscular injections of the test vaccines in stage 2.

1st will be on Visit 2 and 2nd will be on Visit 5, in line with the selected dose regimen in stage 1.


Treatment: Other: GBP560-A
injection volume of 0.5mililiter (mL) with each dose on V2(1day) and V5 (29day) in stage1 and stage2.

Low dose: 3µg Mid dose: 15µg High dose: 50µg

Treatment: Other: GBP560-B
injection volume of 0.5mL with each dose on V2(1day) and V5 (29day) in stage1 and stage2.

Low dose: 3µg Mid dose: 15µg High dose: 50µg

Treatment: Other: IXIARO
injection volume of 0.5mL on V2(1day) and V5 (29day) in stage1 and stage2

Treatment: Other: IMOJEV
injection volume of 0.5mL on V5 (29day) in stage1 and stage2

Treatment: Other: Normal Saline (Placebo)
injection volume of 0.5mL on V2 (1day) in stage1 and stage2 (This is for IMOJEV placebo)
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of participants experiencing any immediate reactions
Timepoint [1] 0 0
30 minutes (2 hours for the sentinel participants in stage 1) post each vaccination
Primary outcome [2] 0 0
Percentage of participants reporting any solicited local Adverse Event (AE)
Timepoint [2] 0 0
during the 7 days following each study vaccination
Primary outcome [3] 0 0
Percentage of participants reporting any solicited systemic Adverse Event (AE)
Timepoint [3] 0 0
during the 7 days following each study vaccination
Primary outcome [4] 0 0
Percentage of participants experiencing any unsolicited Adverse Event (AE)
Timepoint [4] 0 0
during the 28 days following each study vaccination
Primary outcome [5] 0 0
Percentage of participants with any Medically Attended Adverse Event (MAAE)
Timepoint [5] 0 0
until 6 months following the last study vaccination
Primary outcome [6] 0 0
Percentage of participants experiencing any Adverse Event of Special Interest (AESI)s, AEs leading to study withdrawal and Serious Adverse Event (SAE)s during the entire study period
Timepoint [6] 0 0
up to 12 months for stage 1 and up to 24 months for stage 2
Primary outcome [7] 0 0
Seroprotection rate for both the respective and cross Japanese encephalitis virus (JEV) strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers at each time point
Timepoint [7] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.
Primary outcome [8] 0 0
Seroresponse rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers, from baseline to each subsequent time point
Timepoint [8] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination
Primary outcome [9] 0 0
Geometric Mean Titer (GMT) of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) measured by a live-virus neutralization assay (PRNT) at each time point
Timepoint [9] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.
Primary outcome [10] 0 0
Geometric mean fold rise of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2,Beijing-1 strain), measured by a live-virus neutralization assay(PRNT), from each pre-vaccination to each subsequent timepoint
Timepoint [10] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination
Primary outcome [11] 0 0
Geometric mean fold reduction of neutralizing antibody against both respective and cross JEV strains of each vaccine (SA-14-14-2,Beijing-1 strain), measured by live-virus neutralization assay (PRNT) from persistence baseline to each subsequent timepoint
Timepoint [11] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, 12 months, and 24 months following the 2nd study vaccination.
Secondary outcome [1] 0 0
Seroprotection rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers at each time point
Timepoint [1] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination
Secondary outcome [2] 0 0
Seroresponse rate for both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) in live-virus neutralizing antibody titers, from baseline to each subsequent time point.
Timepoint [2] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination
Secondary outcome [3] 0 0
GMT of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2 and Beijing-1 strain) measured by a live-virus neutralization assay (PRNT) at each time point
Timepoint [3] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination
Secondary outcome [4] 0 0
Geometric mean fold rise of neutralizing antibody against both the respective and cross JEV strains of each vaccine (SA14-14-2,Beijing-1 strain), measured by live-virus neutralization assay(PRNT), from each pre-vaccination to each subsequent timepoint
Timepoint [4] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination.
Secondary outcome [5] 0 0
Geometric mean fold reduction of neutralizing antibody against both respective and cross JEV strains of each vaccine (SA-14-14-2,Beijing-1 strain),measured by live-virus neutralization assay(PRNT) from persistence baseline to each subsequent timepoint
Timepoint [5] 0 0
At baseline, 2 weeks, 4 weeks following the 1st study vaccination, and at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months following the 2nd study vaccination.
Secondary outcome [6] 0 0
Cell-mediated response for cytokines expressed by Cluster of Differentiation 4+ Cluster of Differentiation 8+ T cells (Interferon-?, Tumor Necrosis Factor-a, measured by Fluorescence-Activated Cell Sorting-Intracellular Cytokine Staining assay.
Timepoint [6] 0 0
At baseline, 4 weeks following the 1st study vaccination, and at 4 weeks and 6 months following the 2nd study vaccination

Eligibility
Key inclusion criteria
[Age]

1. For Stage 1, participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.

For Stage 2, participant must be 18 years of age and older, at the time of signing the informed consent.

[Type of Participant and Disease Characteristics]
2. Participants who are healthy as determined by medical evaluation including medical history, vital signs, physical examination, clinical laboratory tests and medical judgement of the investigator.
3. Participants who are willing and able to attend all scheduled visits and comply with all study procedures.
4. Body mass index (BMI) within the range of 18.5-29.9 kg/m2 (inclusive) at screening

[Sex and Contraceptive/Barrier Requirements]
5. All participants must agree to be heterosexually inactive or agree to consistently use at least one acceptable method of contraception from at least 4 weeks prior to the 1st study vaccination to 12 weeks after the last study vaccination (Visit 9) (See Appendix 10.4 for detailed contraceptive methods).
6. Female participants with a negative urine or serum pregnancy test at screening.

* Female participants who are surgically sterile (e.g., having undergone a full hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal with amenorrhea for at least 12 months are not subject to a pregnancy test.

[Informed Consent]
7. Participants who are capable of giving signed informed consent as described in Appendix 10.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol before initiation of any trial-specific procedures.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
[Medical Conditions]

1. Any clinically significant respiratory symptoms (e.g., cough, sore throat), febrile illness (tympanic temperature >38°C), or acute illness within 24 hours prior to the 1st study vaccination. Prospective participants with these conditions cannot be included until 24 hours after resolution.
2. History of congenital, hereditary, acquired immunodeficiency, or autoimmune disease.
3. Any positive test results for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening.
4. History of bleeding disorder or thrombocytopenia which is contraindicating intramuscular vaccination in the investigator's opinion.
5. History of hypersensitivity and severe allergic reaction (e.g., anaphylaxis, Guillain-Barre syndrome) to any vaccines or components of the study intervention.
6. History of myocarditis, pericarditis or myopericarditis (including the screening 12-lead ECG results from Stage 1 participants), as assessed by the investigator, indicating probable or possible myocarditis, pericarditis, or myopericarditis, or demonstrating clinically significant abnormalities that could affect participant safety or the interpretation of study findings.
7. History of JEV infection/other flaviviruses infection (e.g., Dengue, West Nile, Zika, St. Louis Encephalitis, Yellow fever).
8. History of malignancy within 1 year prior to the 1st study vaccination (with the exception of malignancy with minimal risk of recurrence at the discretion of the investigator).
9. Significant unstable chronic or acute illness that, in the opinion of the investigator, might pose a health risk to the participant if enrolled, or could interfere with the protocol-specified activities, or interpretation of study results.

* The AESIs as outlined in Section 8.1.4 should be considered for evaluating the participant
10. Any other conditions which, in the opinion of the investigator, might interfere with the evaluation of the study objectives (e.g., alcohol or drug abuse, neurologic or psychiatric conditions).
11. Female participants who are pregnant or breastfeeding.
12. (Only for Stage 1) Current smoker or a recent smoking history within 12 weeks prior to screening. Occasional smoker who smokes up to 10 cigarettes per month may be allowed to participate at the investigator's discretion.

[Prior/Concomitant medication]
13. Receipt of JEV vaccination/other flaviviruses vaccination in the past.
14. Receipt of any vaccine within 4 weeks prior to the 1st study vaccination or planned receipt of any vaccine from enrollment through 4 weeks after the last study vaccination (Visit 8), except for inactivated influenza vaccination, which may be received at least 2 weeks prior to the 1st study vaccination.
15. Receipt of immunoglobulins and/or any blood or blood-derived products within 12 weeks prior to the 1st study vaccination.
16. Receipt of immunosuppressive therapy, such as any use of anti-cancer chemotherapy or radiation therapy; or systemic corticosteroid therapy (=10 mg prednisone/day or equivalent) within 12 weeks prior to the 1st study vaccination. The use of inhaled, topical, or nasal glucocorticoid will be permitted.

[Prior/Concurrent Clinical Study Experience]
17. Participation in another clinical study and receipt of study intervention within 4 weeks prior to the 1st study vaccination, or concurrent, planned participation in another clinical study with study intervention during this study period.

[Other Exclusions]
18. Investigators, or study staff who are directly involved in the conduct of this study or supervised by the investigator, and their respective family members.
19. Donation of = 450mL (milliliter) of blood product within 4 weeks prior to screening, or planned donation of blood product from enrollment through 12 weeks after the last study vaccination (Visit 9).

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
20/02/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
19/03/2028
Actual
Sample size
Target
402
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Nucleus Network - Brisbane (Q Pharm) - Brisbane
Recruitment hospital [2] 0 0
Nucleus Network - Melbourne - Melbourne
Recruitment postcode(s) [1] 0 0
- Brisbane
Recruitment postcode(s) [2] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Central City

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
SK Bioscience Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
Trial website
https://clinicaltrials.gov/study/NCT06680128
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Young-Eun Lee
Address 0 0
Country 0 0
Phone 0 0
+82 2-2008-2337
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06680128